Development of Cellular Models for Osteoblast Response Study to Adipocytic Secretions in an Osteoporosis Context.

NCT04377880 | Completed

• 2 other identifiers: 2019_18R2020-A00027-32
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The recent studies suggest that secretions from medullary adipocytes are involved in the mechanisms of bone loss in osteoporosis (OP) through their actions on neighbouring osteoforming cells, the osteoblasts. The objective of the research is the development of new cellular models representing the aging skeleton to confirm this hypothesis. To this end, osteoblasts will be isolated from human bone fragments coming from femoral heads discarded during total hip replacement surgery. The osteoblastic response to secreted factors released from medullary adipocytes of commercial origin will be analysed using conditioned media incubations. This phenotypic response will be quantified for each subject through the analysis of gene expression levels. Inter-subject phenotype variations will be related to bone density and microarchitecture data obtained by X-ray microtomography. This will assess the existence of a correlation between the osteoblast response to adipocyte secretions and the degree of osteoporosis of the subject from whom the cells are derived.

Conditions

Osteoporosis

Keywords

Bone; Osteoporosis; Osteoblast; Adipocyte; Cellular models

Outcome Measures

Primary Outcomes (1)

• the level of gene expression of adipocyte markers such as PPARG and leptin

  The effect of adipocyte secretion products on osteoblasts will be evaluated by incubating osteoblasts from human bone biopsies with commercially available adipocyte conditioned cell media. Phenotypic changes in osteoblastic cells will then be evaluated by analyzing their gene expression profile and comparing them with those of osteoblasts incubated in unconditioned media. The selected criteria for judging osteoblast alteration will be the measurement of the level of gene expression of adipocyte markers such as PPARG and leptin.

  Baseline

Secondary Outcomes (1)

• Inter-subject phenotype variations by X-ray microtomography

  Baseline

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with a surgical indication for a prosthetic hip joint at the Boulogne-sur-Mer hospital.

You may qualify if:

• Adult subject
• Surgical indication for hip prosthesis implantation
• Affiliation to a social insurance regime

You may not qualify if:

• Rejection of participation
• Diagnosed bone diseases other than osteoarthritis or osteoporosis
• Cancer
• Pregnant Women
• Subject under guardianship or trusteeship
• Subject unable to understand the study.

Sponsors & Collaborators

• University Hospital, Lille: lead
• Universite du Littoral Cote d'Opale: collaborator

Study Sites (1)

Centre hospitalier

Boulogne-sur-Mer, France

Location

Biospecimen

Retention: SAMPLES WITH DNA

Bone fragments; RNA

MeSH Terms

Conditions

Osteoporosis

Condition Hierarchy (Ancestors)

Bone Diseases, Metabolic; Bone Diseases; Musculoskeletal Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Eric FODZO, MD

  University Hospital, Lille

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 5, 2020
• First Posted: May 6, 2020
• Study Start: October 15, 2020
• Primary Completion: September 4, 2024
• Study Completion: September 4, 2024
• Last Updated: December 23, 2025

Record last verified: 2025-12

Locations

FR (1)